Applications of teriparate on jaw osteonecrosis associated with the use of biphosphanates in implantodontics: an integrative review
DOI:
https://doi.org/10.55892/jrg.v7i14.1005Keywords:
Teriparatide, Bisphosphonate-Associated Osteonecrosis of the Jaw, Osteonecrosis, Dental ImplantsAbstract
Dentistry is constantly concerned with the bone quality of its patients. This variable will determine the clinical success of surgical interventions, implant installation, and maintenance of teeth in the oral cavity. In this perspective, patients with osteoporosis are a population that requires greater attention. The current treatment for osteoporosis occurs through the use of bisphosphonates, however, its use is associated with cases of osteonecrosis of the jaws. Teriparatide is a medication that has been studied for the control of bone metabolism and demonstrates potential for dental use. Thus, this study sought to validate the use of teriparatide in the context of bisphosphonate-associated jaw osteonecrosis and its influence on Implantology. Teriparatide is a recombinant parathyroid hormone drug and has anabolic effects on bone metabolism, stimulating osteoblast differentiation and increasing osteocyte activity. Thus, bone anabolism can be thought of as a way to recover clinical conditions with significant losses of mineralized tissue, assisting in the patient's rehabilitation process. In dentistry, the use of teriparatide is associated with higher and better levels of implant osseointegration and positive effects on periodontal tissues. Its use can also be enhanced by supplementation of vitamin D and calcium. In light of these findings, the use of teriparatide may be an alternative for osteoporosis control in the face of bisphosphonates during the period when dental implant installation or bone surgeries in the head and neck region are planned, reducing the risks of necrosis in the area. However, it is important to emphasize that clinical studies still lack more robust experimental designs and larger samples so that teriparatide is truly a valid and safe choice for patients.
Downloads
References
Lee JJ, Cheng SJ, Jeng JH, Chiang CP, Lau HP, Kok SH. Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy. Head Neck. 2011 Sep;33(9):1366-71.
Sigua-Rodriguez EA, da Costa Ribeiro R, de Brito AC, Alvarez-Pinzon N, de Albergaria-Barbosa JR. Bisphosphonate-related osteonecrosis of the jaw: a review of the literature. Int J Dent. 2014;2014:192320
Rollason V, Laverrière A, MacDonald LC, Walsh T, Tramèr MR, Vogt-Ferrier NB. Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ). Cochrane Database Syst Rev. 2016 Feb 26;2(2):CD008455.
Govaerts D, Piccart F, Ockerman A, Coropciuc R, Politis C, Jacobs R. Adjuvant therapies for MRONJ: A systematic review. Bone. 2020 Dec;141:115676.
Kim JW, Kwak MK, Han JJ, Lee ST, Kim HY, Kim SH, et al. Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab. 2021 Nov;28(4):279-296.
Sennerby L, Roos J. Surgical determinants of clinical success of osseointegrated oral implants: a review of the literature. Int J Prosthodont. 1998 Sep-Oct;11(5):408-20.
Gruber R. Auswirkungen der pharmakologischen Osteoporosetherapie in der Zahnheilkunde. J für Klinische Endokrinologie und Stoffwechsel. 2013 Jan;6(1):12-15.
Doh RM, Park HJ, Rhee Y, Kim HS, Huh J, Park W. Teriparatide therapy for bisphosphonate-related osteonecrosis of the jaw associated with dental implants. Implant Dent. 2015 Apr;24(2):222-6.
Lee JJ, Cheng SJ, Jeng JH, Chiang CP, Lau HP, Kok SH. Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy. Head & Neck. 2010;33(9): 1366–1371.
Cheung A, Seeman E. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med. 2010 Dec;363(25):2473-4.
Ortega E, Mourelo J, Castro J, Valinño J, Ferrera M. Treatment with dental implants after extraction. BJIHS. 2020 Mar;2(3):49-63.
Rauber S. Osseodensificação em Implantes dentários: uma revisão de literatura. J. Implantol. Health Sci. 2019 Set;1(4):55-68.
Bispo L, Shitsuka C. Uso de implantes angulados na reabilitação oral: planejamento reverso. Rev Odontol. 2017 Mai;29(2):174-183.
Rodrigues M, Costa A, Dietrich L. Immediate load unit implants: possibility of oral and aesthetic rehabilitation – literature review. RSD. 2021 Aug;10(11):e237101119546.
Ottesen C, Andersen S, Jensen S, Kofod T, Gotfredsen K. Medication-related osteonecrosis of the jaw and successful implant treatment in a patient on high- dose antiresorptive medication: A case report. Clin Exp Dent Res. 2022;8(5):1059-1067.
Inoue M, Matsumoto C, Nakajima K, Kuroshima S, Sawase T. Alendronate/dexamethasone combination therapy worsens soft and hard tissue wound healing around implants in rat maxillae. Bone. 2021 Jul;148:115942.
Jung R, Al-Nawas B, Araujo M, Avila-Ortiz G, Barter S, Brodala N, et al. Group
ITI Consensus Report: The influence of implant length and design and medications on clinical and patient-reported outcomes, Clin. Oral Implants Res. 2018 Oct;29:69–77.
Brandão CM, Lima MG, Silva AL, Silva GD, Guerra AA Jr, Acúrcio Fde A. Treatment of postmenopausal osteoporosis in women: a systematic review. Cad Saude Publica. 2008;24 Suppl 4:s592-606.
Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996 Jun 15;97(12):2692-6.
Allen MR, Erickson AM, Wang X, Burr DB, Martin RB, Hazelwood SJ. Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone. Calcif Tissue Int. 2010 Jan;86(1):67-71.
Sampaio FC, Veloso HHPV, Barbosa D do N. Bisphosphonates Mechanisms of Action and it’s Influence in the Endodontic Treatment Prognosis. Rev. Fac. Odontol. 2010 Jan-Apr;51(1):31-38.
Ferreira Junior CD, Casado PL, Barboza LSP. Osteonecrose Associada aos Bifosfonatos na Odontologia. R. Periodontia. 2007 Dez;17(4):24-30.
Levin L, Laviv A, Schwartz-Arad D. Denture-related osteonecrosis of the maxilla associated with oral bisphosphonate treatment. J Am Dent Assoc. 2007 Sep;138(9):1218-20.
O'Ryan FS, Lo JC. Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. J Oral Maxillofac Surg. 2012 Aug;70(8):1844-53.
Carvalho A, Mendes RA, Carvalho D, Carvalho JFC. Osteonecrose da mandíbula associada a bifosfonatos intravenosos em doentes oncológicos. Acta. Med. Port. 2008 Set;21(5):505-510.
Edwards BJ, Hellstein JW, Jacobsen PL, Kaltman S, Mariotti A, Migliorati CA; American Dental Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteonecrosis of the Jaw. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2008 Dec;139(12):1674-7.
Lindsay R, Krege JH, Marin F, Jin L, Stepan JJ. Teriparatide for osteoporosis: importance of the full course. Osteoporos Int. 2016 Aug;27(8):2395-410.
Neer RM, Arnaud CD, Zanchetta JR,Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parath0yroid hormone. J Clin Invest. 1999 Aug;104(4):439-46.
Oliveira JHA, Bracco OL, Kayath M, Guarniero R. Teriparatide (PTH[1-34]rh): a new perspective in the treatment of osteoporosis. Acta Ortop Bras. 2009 Aug;11(3).
Lindsay R, Nieves J, Henneman E, Shen V, Cosman F. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone- (1-34): kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab. 1993 Dec;77(6):1535-9.
Cosman F, Nieves J, Woelfert L, Gordon S, Shen V, Lindsay R. Parathyroid responsivity in postmenopausal women with osteoporosis during treatment with parathyroid hormone. J Clin Endocrinol Metab. 1998 Mar;83(3):788-90.
Manolagas SC. Osteocalcin promotes bone mineralization but is not a hormone. PLoS Genet. 2020 Jun;16(6):e1008714.
Zushi Y, Takaoka K, Tamaoka J, Ueta M, Noguchi K, Kishimoto H. Treatment with teriparatide for advanced bisphosphonate-related osteonecrosis of the jaw around dental implants: a case report. Int J Implant Dent. 2017 Dec;3(1):11.
Narongroeknawin P, Danila MI, Humphreys LG Jr, Barasch A, Curtis JR. Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report. Spec Care Dentist. 2010 Mar-Apr;30(2):77-82.
Kuchler U, Luvizuto ER, Tangl S, Watzek G, Gruber R. Short-term teriparatide delivery and osseointegration: a clinical feasibility study. J Dent Res. 2011 Aug;90(8):1001-6.
Silverman SL, Nasser K. Teriparitide update. Rheum Dis Clin North Am. 2011 Aug;37(3):471-7, vii.
Kim KM, Park W, Oh SY, Kim HJ, Nam W, Lim SK, Rhee Y, Cha IH. Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw. Osteoporos Int. 2014 May;25(5):1625-32.
Avolio G, Brandão C, Marcucci M, Alonso G. Use of the plasma CTX for assessing the bone activity of the mandible among osteopenic and osteoporotic patients. Braz Oral Res. 2010 Apr-Jun;24(2):250-5.
Agnihotri R, Gaur S. Applications of teriparatide for alveolar bone regeneration: A systematic review. J Int Soc Prevent Communit Dent. 2021;11:639-43.
Tsai KY, Huang CS, Huang GM, Yu CT. More on the resolution of bisphosphonate-associated osteonecrosis of the jaw. J Rheumatol. 2010 Mar;37(3):675; author reply 676.
Sarmiento L AK. Resolution without surgery of an advanced stage of medication-related osteonecrosis of the jaw (MRONJ) in a patient who could not suspend her treatment for osteoporosis. Oral Oncol. 2019 Dec;99:104318.
Kim JY, Park JH, Jung HD, Jung YS. Treatment of Medication-Related Osteonecrosis of the Jaw Around the Dental Implant With a Once-Weekly Teriparatide: A Case Report and Literature Review. J Oral Implantol. 2019 Oct;45(5):403-407.
Tennis P, Rothman KJ, Bohn RL, Tan H, Zavras A, Laskarides C, Calingaert B, Anthony MS. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf. 2012 Aug;21(8):810-7.
